The global market for prostate cancer market is likely to be valued at around US$ 10.92 Billion in 2023 and is projected to expand at a CAGR of 8.5% through 2033. The market is expected to reach US$ 24.7 Billion by 2033.
Cancer patients can benefit from physical exercise in a number of ways, including improving their quality of life and their ability to do basic tasks. Physical exercise has also been associated with a lower progression rate and longer survival rates following a prostate cancer diagnosis. Despite the advanced state of prostate cancer, a new study reports how exercising high intensity for a short while has the ability to boost tumor-suppressing responses to a great extent.
Currently, metastatic prostate cancer is associated with substantial annual healthcare costs, which have increased over time as new oral therapies for the treatment of metastatic prostate cancer have been approved. USA population-level incidence of metastatic prostate cancer decreased after prostate cancer screening with PSA testing was widely adopted.
Future generations will be among the first to witness more affordable, accessible, and diagnostic-associated treatment approaches for prostate cancer as the incidence of the disease increases in the future. In an attempt to address the challenges faced by prostate cancer research organizations & societies, governments are investing in numerous initiatives that are meant to raise awareness about the disease, thereby assisting them in developing effective medications.
Data Points
Key Statistics
Anticipated Base Year Value (2022)
US$ 10.1 Billion
Expected Market Value (2023)
US$ 10.92 Billion
Projected Forecast Value (2033)
US$ 24.7 Billion
Global Growth Rate (2023 to 2033)
8.5% CAGR
North America Market Share(2023)
45%
North America Market Value (2023)
US$ 4.2 Billion
Europe Market Share (2023)
US$ 32%
Europe Market Value (2023)
US$ 5.3 Billion
China Market Share (2023)
26%
China Market Value (2023)
US$ 3.1 Billion
Expected Market Share of Top 3 Countries
65%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Prostate Cancer (2018 to 2022) Vs. Market Forecast Outlook (2023 to 2033)
According to Future Market Insights prostate cancer sales grew at a CAGR of 4.8% in the historical period 2018 to 2022. As the geriatric population in developed countries increases along with affordable top-notch healthcare, the prostate cancer market is expected to grow. Governing agencies and private providers are both increasing their healthcare expenditures rapidly.
FDA approvals of various technologies for prostate cancer treatment are anticipated to drive the market in the coming years. For instance, iQuest, a software application program powered by artificial intelligence (AI) for managing prostate cancer patients, has been cleared by the FDA under 510(k). Through the use of deep-learning algorithms and existing diagnostic information, iQuest creates a tailored [3D] map of the prostate that shows where the cancer is located.
In response to the factors listed above, the prostate cancer market is predicted to grow in sales. Accordingly, the market for prostate cancer is projected to grow at a CAGR of 5.2% between 2023 and 2033.
What Factors are driving High Demand for Food Allergies Worldwide?
Prostate Cancer Prominence will drive Diagnostic and Drug Development Demand
As the prevalence of prostate cancer increases, hormonal drugs are being used more frequently to treat hormone-naive and non-metastatic prostate cancer. With a lot of untapped potential in developing countries, there are a lot of potential market opportunities. Prostate cancer market growth may also be attributed largely to unmet treatment needs, increasing awareness among the general public, and advancements in the healthcare field during the forecast period. In addition, new opportunities will likely arise from the expiration of patents on significant drugs such as Zytiga.
A growing number of internet users and an increase in awareness about online pharmacies are all expected to play a role in improving the trend of online drug purchases over traditional methods, leading to a higher adoption rate of drugs. For example, the Xtandi drug is anticipated to grow at the fastest rate over the next few years due to the fact that it is highly adopted by patients and the drug has been used for longer periods of time than other drugs in the market.
MRC Clinical Trials Unit at UCL and other institutes are currently conducting new trials. According to a publication by the institute in June 2022, chemotherapy such as docetaxel improves the survival rate of prostate cancer patients with secondary tumors by 39%. Prostate cancer patients are getting a more effective way to treat their disease with a personalized approach. Further, rucaparib has been approved by the Food and Drug Administration for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious BRCA mutation (germline and/or somatic) after receiving chemotherapy based on taxans and androgen receptors. Thus, prostate cancer therapies will be adopted more widely, thereby driving the market growth. All of the factors mentioned above are expected to propel the market at high growth rates.
Studies Conducted by a Variety of Researchers are expected to Drive Market Funds for Future Prostate Cancer Therapies
A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Additionally, there are more affordable options for men with localized, lower-risk prostate cancer. By using a treatment method called focal therapy, only the parts of the prostate that contain cancerous cells are destroyed, while the other tissue of the prostate remains unharmed.
Cold, heat, or electrical impulses are the methods of delivering focal therapy, which is a minimally-invasive solution. In addition to other focal therapies, TULSA is also a minimally invasive treatment that also offers additional benefits, such as the ability to protect surrounding tissues. Further, new approaches to treating and detecting prostate cancer are being explored on an ongoing basis, including a genetic screening program, PSMA-targeting drugs, and immunotherapy.
Further, liquid biopsies may change the way cancer is treated in the future, as they allow for a more bespoke approach. Blood tests that pick up tumor DNA circulating in the bloodstream are a better method for analyzing tumor DNA than conventional tissue biopsies, which involve surgically removing a piece of the tumor. Furthermore, UC San Diego Health offers the first novel treatment option in the region for patients with prostate cancer that is resistant to conventional treatment. The new radiation pharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the FDA for injection or infusion. PSMA, a protein found on most prostate cancer cells, is the marker for the drug, which moves throughout the body and targets cancer cells. The cancer cells are then damaged and killed by radiation.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Prostate Cancer Market?
Failure to Provide Drugs and Treatments on Time is Stifling Growth in Developing Nations
It is projected that there will be a substantial limitation on the global market as a result of the high cost of targeted therapies and other immunotherapies. Developing countries, especially in the field of therapeutics, are expected to be constrained by a low level of awareness of technological advancements in the therapeutic area. As reimbursement policies are constantly changing, time spans used for treatment are extending, combination therapies are becoming more and more costly, and managing the life cycle of drugs is becoming a challenge, interfering with the prostate cancer market's growth.
In Moreover, the lack of skilled personnel to supervise laboratory equipment is slowing the growth of the prostate cancer market, as the shortage of skilled workers is causing the market to deteriorate. Further, government policies constantly change, which makes it hard for the market to grow. Prostate cancer medicines in developing nations are in short supply and treatment times are extended, which is expected to restrict the market's growth.
Additionally, low success rates in clinical trials and high costs may limit the market. In addition, medical consultation fees and the high cost of tissue biopsy are expected to limit the growth of the industry. As a result, there may also be problems with the adoption rate of treatment techniques such as issues with inadequate reimbursement of treatment expenses.
Start-ups for Prostate Cancer Market
Positive Changes for Prostate Cancer Results from New Entrants
Technological advancements in the prostate cancer field are enabling new companies to enter the market and gain a competitive advantage. Research and development is a constant investment for these companies as they strive to stay ahead of changing consumer preferences. In order to improve its position in the prostate cancer market, the company strives to advance the market.
Prostate Mapping offers transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) to diagnose prostate cancer. The prostate biopsy is performed under anesthesia with an MRI scan as part of the template. Nuada's medical prostate care includes prostate mapping.
Cancer Targeted Technology (CTT) is a research and development company that is working on developing enzyme inhibitors of small molecular weight that have imaging and drug delivery capabilities for their use in the diagnostics and treatment of cancer. Its lead product, CTT-54, targets circulating tumor cells and delivers radio-photo- and chemotherapeutics targeted to the overexpressed Prostate Specific Membrane Antigen (PSMA). CTT-54 PET diagnostic is claimed to be able to image within an hour and determine personalized treatment choices with the capability of monitoring them.
Prostatype is anonline platform for second opinions on prostate cancer. Users have the option of booking appointments and providing the necessary information for initial assessments and medical advice using the platform. For biopsy tests, a referral and contact information for the urologist is provided. In order to determine the treatment plan, medical second opinions are given based on the test results and previous assessments.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Comparative View of Adjacent Prostate Cancer Markets
Prostate Cancer Market:
Attributes
Prostate Cancer Market
CAGR (2023 to 2033)
8.5%
Market Value (2033)
US$ 24.7 Billion
Growth Factor
Sales of prostate cancer products are driven by the prevalence of prostate cancer, unhealthy lifestyles, and the demand for early treatment.
Opportunity
Oral chemotherapy and drug development are expected to grow in demand, creating lucrative market opportunities.
Prostate Cancer Diagnostics Market:
Attributes
Prostate Cancer Diagnostics Market
CAGR (2023 to 2033)
11%
Market Value (2033)
US$ 9 Billion
Growth Factor
Regular checkups and early treatment of prostate cancer are driving the market for prostate cancer diagnostics. In addition, non-universal tests have led to people focusing on timely detection and nudging growth.
Opportunity
PCA3 and PSA tests represent the highest market potential in the prostate cancer diagnostics market. Consequently, the future market will present lucrative opportunities.
Cancer Immunotherapy Market:
Attributes
Cancer Immunotherapy Market
CAGR (2023 to 2033)
12%
Market Value (2033)
US$ 182.4 Billion
Growth Factor
A growing incidence of cancer, increasing Research and Development funding, and technological developments in therapies are major factors driving global demand for cancer immunotherapy.
Opportunity
A rise in demand for monoclonal antibodies and a higher prevalence of cancer are both contributing to the growth of the global cancer immunotherapy market.
Regional Insights
Why is the North American prostate cancer Market Experiencing Significant Revenue Growth?
Enhanced Advancements in Treatments and Devices Along with Investments to Grow the Market
According to the forecast, North American revenues are expected to accumulate a revenue share of 45% in 2023. As prostate cancer diagnosis investments rise in North America, the region will dominate the market. Due to high health awareness and the availability of modern diagnostic facilities, the USA dominates the North American market.
According to the American Cancer Society, prostate cancer is the number one form of cancer that is diagnosed among men and one of the leading causes of death from cancer in the USA. The reason behind this is that there is a lack of understanding of the cellular factors involved in the progression of the disease and the risk of developing castration-resistant prostate cancer (CRPC). Recent recommendations against routine prostate cancer screening with prostate-specific antigen may have contributed to a rise in metastatic prostate cancer in the USA American men are most likely to develop prostate cancer than skin cancer. According to the American Cancer Society, there will be 268,490 new cases of prostate cancer diagnosed in the USA in 2022. About 34,500 people will die from prostate cancer.
It is anticipated that patients will seek early diagnosis due to the increased awareness of timely detection, which will spur the government to invest in research and development, thereby increasing the opportunity for growth. For instance, The National Cancer Institute funds researchers who are researching how to detect, prevent, and treat prostate cancer. A study by NCI researchers examines how often and how early prostate cancer occurs in men at high risk using magnetic resonance imaging (MRI). In addition, the researchers are researching whether regular scans for such men can detect cancer early on before it spreads to other parts of the body (metastasize).
How will the Prostate Cancer Market in Europe Make Significant Profits?
European Prostate Cancer Market to be Blown Away by New Therapies and Drugs
According to estimates, Europe is expected to dominate the global market. A substantial portion of the revenues generated worldwide is generated in this region, accounting for 32% of the total revenue generated globally. Among European men, prostate cancer is the most common form of cancer, with 473,000 cases diagnosed annually. There is a 30% survival rate for CRPC among these patients, which is 10% to 20% within five years.
An increasing number of studies and Research and Development activities are being carried out in this region to treat prostate cancer. Many researchers are focusing their efforts on developing therapies and drugs that will be available on the market in the near future. For instance, Lynparza-based combination therapy will be available for the first time in the EU to patients with advanced prostate cancer. For men with metastatic castration-resistant prostate cancer (mCRPC) who do not require chemotherapy but are not eligible for chemotherapy, Lynparza (olaparib) has been approved by the European Commission (EC) when combined with abiraterone, prednisone, or prednisolone. With the combination of a new hormonal agent and the poly(ADP-ribose) polymerase (PARP) inhibitor, this is the first approved PARP inhibitor that has demonstrated clinically meaningful benefits.
Category-Wise Insights
What is the most Promising Treatment Type for Prostate Cancer?
New Treatment Therapies will drive Oral Chemotherapy Growth
As a matter of fact, Future Market Insights anticipates that chemotherapy will continue to dominate the market throughout the forecast period. The chemotherapy market is expected to comprise 12% of all medical treatments. Due to increasing cancer prevalence levels and the growing necessity to treat these diseases, cancer treatment requirements are on the rise.
As governments invest in healthcare, patients in different economies have access to sophisticated healthcare facilities, providing a boost to chemotherapy markets. Moreover, the pharma industry is conducting intensive development work to launch new cancer treatments, which is anticipated to drive the growth of the chemotherapy market in the future.
As a result of an increase in demand for oral health products, the oral drug is expected to witness the fastest growth during the forecast period. Drugs are available in many forms through oral administration, and patients can take them at home very easily. Its demand is also likely to be boosted in the near future by manufacturers conducting extensive research and development to launch novel oral drugs. Advanced prostate cancer is often treated with oral chemotherapy. For instance, Orgovyx (relugolix) has been approved for the treatment of advanced prostate cancer in adults by the USA Food and Drug Administration.
What is the Future of Online Pharmacies?
In the evaluation period, the online pharmacy segment will represent 28% of the market and grow at a CAGR of 4.5%. As online pharmacy purchases have become more popular than traditional methods of ordering drugs, a steady increase in the number of online pharmacies is predicted. Increasing awareness of online pharmacies and the number of internet users are both contributing to the growth of the online purchase market.
Online pharmacy sales have grown significantly due to the growth of the e-commerce industry as well as home delivery services offered by various companies. Moreover, the growing trend of online discounts on expensive medications and tests is expected to increase demand for online pharmacies even further. In continuing to develop the online pharmacy market for prostate cancer drugs, increased online advertisements and promotions of various medicines are expected to have a positive impact on the market demand for online pharmacies.
Market Competition
Prostate cancer is highly fragmented and competitive, with several domestic and regional players playing. Artificial intelligence is being used by major players in the prostate cancer market to study the tissues and determine the accuracy of their results.
Cipla Limited launched LeuprolideAcetateInjection Depot 22.5mg. According to the USFDA's 505(b)(2) regulatory pathway, the product was approved through a New Drug Application (NDA). It is used to treat advanced prostate cancer as a palliative measure. In addition to treating anemia caused by uterine fibroids, it is also indicated for endometriosis.
In patients with metastatic castration-resistant prostate cancer who have PSMA-positive cancer, Novartis Pluvicto shows statistically significant and clinically meaningful radiographic benefits. This announcement marks the first time that Pluvicto has demonstrated significant benefits for people with prostate cancer of this type who haven't been treated with taxane-based chemotherapy since it was approved as a PSMA-targeted radioligand therapy.
Key Segments Profiled in the Prostate Cancer Industry Survey
What was the total market value of prostate cancer in 2022?
The prostate cancer treatment market was valued at US$ 10.1 Billion in 2022
What's the estimated value of the prostate cancer industry by 2023?
According to FMI, the prostate cancer market is expected to reach US$ 10.92 billion by 2023.
What is the expected percentage rise in the market for prostate cancer until 2033?
From 2023 to 2033, FMI expects prostate cancer revenue to flourish at an 8.5% CAGR
What is the expected market value for prostate cancer in 2033?
The prostate cancer market is expected to reach US$ 24.7 billion by 2033
How do growth prospects for prostate cancer appear in North America?
More than 45% of industry revenues are expected to come from the North American market in 2023.
How do growth prospects for prostate cancer appear in the Europe?
Market share of prostate cancer in Europe is projected to increase to 32% by 2033.
Who are the top 5 market players in the prostate cancer market?
Johnson & Johnson Services, Inc., Astellas Pharma Inc., Eli Lilly and Company, Sanofi, Ipsen Pharma are the top 5 market players in the prostate cancer market.
What is the outlook for prostate cancer in the Asia Pacific?
Market share for prostate cancer in Asia Pacific is forecast to reach 26% by 2033.
Which end-use area is expected to hold the largest share of the prostate cancer market in the future?
Prostate cancer in online pharmacies will account for 28% of the market by 2023.
Table of Content
1. Executive Summary | Prostate Cancer Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Hormonal Therapy
5.3.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
5.3.1.1.1. Zytiga
5.3.1.1.2. Gonax
5.3.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
5.3.1.2.1. Lupron
5.3.1.2.2. Zoladex
5.3.1.2.3. Eligard
5.3.1.2.4. Decapeptyl
5.3.1.2.5. Vantas
5.3.1.2.6. Others
5.3.1.3. Anti-Androgen
5.3.1.3.1. Xtandi
5.3.1.3.2. Casodex
5.3.2. Chemotherapy
5.3.2.1. Taxotere
5.3.2.2. Jevtana
5.3.3. Immunotherapy
5.3.3.1. Provenge
5.3.4. Targeted Therapy
5.3.4.1. Xofigo
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores & Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia & Pacific
7.3.5. East Asia
7.3.6. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States of America
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Australia
11.2.1.6. New Zealand
11.2.1.7. Rest of South Asia & Pacific
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. United States of America
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Drug Class
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Drug Class
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Drug Class
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Drug Class
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Drug Class
14.5.2.2. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Drug Class
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Drug Class
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Drug Class
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Drug Class
14.9.2.2. By Distribution Channel
14.10. India
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Drug Class
14.10.2.2. By Distribution Channel
14.11. Malaysia
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Drug Class
14.11.2.2. By Distribution Channel
14.12. Singapore
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Drug Class
14.12.2.2. By Distribution Channel
14.13. Thailand
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Drug Class
14.13.2.2. By Distribution Channel
14.14. Australia
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Drug Class
14.14.2.2. By Distribution Channel
14.15. New Zealand
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Drug Class
14.15.2.2. By Distribution Channel
14.16. China
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Drug Class
14.16.2.2. By Distribution Channel
14.17. Japan
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Drug Class
14.17.2.2. By Distribution Channel
14.18. South Korea
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Drug Class
14.18.2.2. By Distribution Channel
14.19. GCC Countries
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Drug Class
14.19.2.2. By Distribution Channel
14.20. South Africa
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Drug Class
14.20.2.2. By Distribution Channel
14.21. Israel
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2022
14.21.2.1. By Drug Class
14.21.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Johnson & Johnson Services, Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Astellas Pharma Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Eli Lilly and Company
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Sanofi
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Ipsen Pharma
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Bayer AG
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. AstraZeneca
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Valeant Pharmaceuticals International, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Merck & Co., Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Pfizer Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: South Asia & Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia & Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: South Asia & Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 21: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia & Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: South Asia & Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: South Asia & Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia & Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia & Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 68: South Asia & Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 69: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 70: South Asia & Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: South Asia & Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 74: South Asia & Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: South Asia & Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 92: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 98: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 99: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 100: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 104: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: MEA Market Attractiveness by Country, 2023 to 2033
